You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Sentinel 4.0TM: Measurement and Control System for 3DCP Interlayer Bond Strength

    SBC: APPLIED RESEARCH TRANSFORMATION, PLLC            Topic: 2

    The construction industry is poised for a major transformation through the additive manufacturing approach of field-based concrete printing, an emerging technology using large-scale 3D printers to construct physical infrastructure. Most 3D printing is performed in a controlled environment. In field-based construction, many factors, especially environmental ones, affecting printed concrete product ...

    SBIR Phase I 2023 Department of CommerceNational Institute of Standards and Technology
  2. Accelerating adoption of anti-phishing authentication methods

    SBC: ROWND INC            Topic: 3

    President Biden’s new 2023 National Security Strategy outlines the need to shift the burden of security from individuals and small businesses to large institutions. Password-based authentication puts individuals and organizations at risk, but moving towards passwordless technologies is hard due to the overwhelming number of choices and the lack of data around the unmitigated costs. Inline with t ...

    SBIR Phase I 2023 Department of CommerceNational Institute of Standards and Technology
  3. CN-105 Improves Functional Outcome After Intracranial Hemorrhage

    SBC: AegisCN LLC            Topic: 106

    Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Boron-containing antimalarial drug discovery

    SBC: REACTIVE BIOSCIENCES INC            Topic: NIAID

    PROJECT SUMMARY New drugs to treat malaria, ideally with unique chemical structures and mechanisms of action, are urgently needed. Optimal drug candidates for the treatment and prevention of malaria will have potent activity against cultured parasites and in animal models of malaria, be rapidly active against erythrocytic malaria parasites, be orally bioavailable, have extended pharmacological exp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. THERAPY FOR ALCOHOL USE DISORDER

    SBC: ARTIAM BIO INC.            Topic: 150

    Abstract Alcohol use disorder (AUD) is a major global health issue. In the US, AUD affects over 14 million people over the age of 18. While there are three approved drugs for AUD, less than 4% of patients eligible for pharmacotherapy are prescribed a medication – likely due to limited efficacy of currently approved agents. Also, the relapse rate for AUD continues to be exceedingly high. Thus, ne ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Intravaginal device for the treatment of pelvic pain and dyspareunia in female cancer survivors

    SBC: CERVU, INC            Topic: NICHD

    Summary: More than half of female cancer survivors will experience chronic pelvic pain and dyspareunia (painful intercourse) due to their cancer treatments. As the number of cancer survivors continues to grow, so too will the number of women in need of effective treatments for this life-altering condition. Pelvic floor physical therapists currently use several different devices during in-clinic an ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Temperature Modulation with Smart Radiometric Monitoring for Effective and Long-Lasting Opioid-Free Pelvic Pain Relief- A NovelLow-Cost, Portable, Tampon-sized Thermal Transfer Device.

    SBC: H3PELVIC THERAPY SYSTEMS, INC.            Topic: NICHD

    ABSTRACT Pelvic pain (PP) is associated with more than 20 different, clinically identified, maladies, such as Urinary Tract Infection (UTI), Menstrual Cramps (MC), Endometriosis (EM), Overactive Bladder (OAB) and Interstitial cystitis/Painful bladder syndrome (IC/PBS). These painful and debilitating conditions often have a dramatic negative impact on the quality of life (QOL) of millions of PP suf ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility

    SBC: Anelleo, Inc.            Topic: NICHD

    Abstract - Infertility affects ~13-15% of reproductive-aged couples in the US. The success of in vitro fertilization (IVF), the most used Assisted Reproductive Technology (ART), depends on sustained exogenous progesterone supplementation to establish and maintain pregnancy. This supplementation must be administered over 8 to10 weeks of gestation until placental progesterone production is adequate ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. An Aptamer-directed IgG1-Fc Drug Conjugate (AFDC) for Treating Pancreatic Cancer

    SBC: ONCOTRAP INC            Topic: 102

    AbstractPancreatic ductal adenocarcinoma (PDAC) ranks the seventh in causing cancer-related death among all human cancers with very poor prognosis and horrendous survival rate. Despite the use of gemcitabine/nab- paclitaxel and FOLFIRINOX, the median survival rates for patients with metastatic PDAC are still less than one year. Immune checkpoint inhibitor had little responses against PDAC in clini ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Improving parent-adolescent communication about sexual and reproductive health

    SBC: Teen Health Research, Inc.            Topic: NICHD

    PROJECT SUMMARY Early adolescence, between the ages of 10-13, is a critical time for sexuality development. It is a period when most young people enter puberty and have new questions about bodies, relationships, and sexual activity. However, the majority of US adolescents enter this early adolescent period without access to the kind of inclusive, comprehensive sex education that could help them de ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government